Loading
Life sciences · Phase 2/3 Trial
ClinicalTrials.gov · October 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2/3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07079735). This is a study registration, not published results. Lead sponsor: Columbia University. Recruitment status: RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection. Interventions: DRUG: Letermovir; DRUG: Valganciclovir. Primary outcome measures: Occurrence of leukopenia , During the duration of CMV prophylaxis (6 months for moderate risk and 12 months for high risk from start of therapy); Occurrence of neutropenia , During the duration of CMV prophylaxis (Up to 6 months for moderate risk and up to 12 months for high risk from start of therapy). Brief summary: The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.